Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT, CAPEOX, Bevacizumab, and Tislelizumab in RAS-Mutant MSS mCRC
NCT06835179Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in metastatic colorectal cancer (mCRC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 1 year. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06835179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835179.